Development Progress In 2018 For Acute Ischemic Stroke Drugs Will Fuel Market Growth

- 

ACTIVASE (ALTEPLASE) is currently the only FDA-approved drug available for the treatment of acute ischemic stroke (AIS) in the 8MM (US, France, Germany, Italy, Spain, UK, Japan and China); however, novel drugs designed to improve clinical outcomes of AIS patients will start launching from 2021, which along with the increasing prevalence of AIS, will fuel AIS market growth.

GlobalData report, ‘Acute Ischemic Stroke: Global Drug Forecast and Market Analysis to 2027’ states that the AIS pipeline is fairly strong, consisting of around 36 pipeline candidates under development including neuroprotective agents (44 per cent), stem cell therapies (14 per cent), and drugs for stroke recovery (11 per cent). Conversely, the AIS pipeline contains only three thrombolytic drugs and very few drugs for prevention of stroke recurrence.